During public health crises like the COVID-19 pandemic, ultraviolet-C (UV-C) decontamination of N95 respirators for emergency reuse has been implemented to mitigate shortages. However, decontamination efficacy across N95s is poorly understood, due to the dependence on received UV-C dose, which varies across the complex three-dimensional N95 shape. Robust quantification of UV-C dose across N95 facepieces presents challenges, as few UV-C measurement tools have sufficient 1) small, flexible form factor, and 2) angular response. To address this gap, we combine optical modeling and quantitative photochromic indicator (PCI) dosimetry with viral inactivation assays to generate high-resolution maps of “on-N95” UV-C dose and concomitant SARS-CoV-2 viral inactivation across N95 facepieces within a commercial decontamination chamber. Using modeling to rapidly identify on-N95 locations of interest, in-situ measurements report a 17.4 ± 5.0-fold dose difference across N95 facepieces, yielding 2.9 ± 0.2-log variation in SARS-CoV-2 inactivation. UV-C dose at several on-N95 locations was lower than the lowest-dose locations on the chamber floor, highlighting the importance of on-N95 dose validation. Overall, we couple optical simulation with in-situ PCI dosimetry to relate UV-C dose and viral inactivation at specific on-N95 locations to inform the design of safe and effective decontamination protocols.
Clinical Study in the Treatment of Patients With COVID-19 - Condition: COVID-19
Interventions: Drug: Molixan; Drug: Placebo
Sponsor: Pharma VAM
Recruiting
Diagnostic Performance of the ID Now™ COVID-19 Screening Test Versus Simplexa™ COVID-19 Direct Assay - Condition: Covid19
Intervention: Diagnostic Test: ID Now™ COVID-19 Screening Test
Sponsor: Groupe Hospitalier Paris Saint Joseph
Active, not recruiting
Dose-Ranging Study to Assess the Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19 - Condition: COVID-19
Interventions: Drug: Melatonin; Drug: Placebo
Sponsors: State University of New York at Buffalo; National Center for Advancing Translational Science (NCATS)
Not yet recruiting
A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19 - Condition: COVID-19
Interventions: Drug: Brilacidin; Drug: Placebo; Drug: Standard of Care (SoC)
Sponsor: Innovation Pharmaceuticals, Inc.
Recruiting
Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19 - Condition: Covid19
Interventions: Biological: VIR-7831 (Gen1); Biological: VIR-7831 (Gen2)
Sponsors: Vir Biotechnology, Inc.; GlaxoSmithKline
Recruiting
DCI COVID-19 Surveillance Project - Condition: Covid19
Intervention: Diagnostic Test: SARS-CoV-2 RT-PCR Assay for Detection of COVID-19 Infection
Sponsors: Temple University; Dialysis Clinic, Inc.
Recruiting
Off-the-shelf NK Cells (KDS-1000) as Immunotherapy for COVID-19 - Condition: Covid19
Interventions: Biological: KDS-1000; Other: Placebo
Sponsor: Kiadis Pharma
Not yet recruiting
A Study to Assess if a Medicine Called Bamlanivimab is Safe and Effective in Reducing Hospitalization Due to COVID-19 - Condition: Covid19
Interventions: Biological: Bamlanivimab; Other: Standard of Care
Sponsors: Fraser Health; Fraser Health Authrority Department of Evaluation and Research Services; Surrey Memorial Hospital Foundation; University of British Columbia; Centre for Health Evaluation and Outcome Sciences; BC Support Unit; Abcellera; Surrey Memorial Hospital Clinical Research Unit
Not yet recruiting
Effects of Telerehabilitation After Discharge in COVID-19 Survivors - Condition: Covid19
Intervention: Other: Telerehabilitation
Sponsor: Hacettepe University
Recruiting
Corticosteroids for COVID-19 - Condition: Covid19
Interventions: Drug: Prednisone; Device: Point of Care testing device for C-reactive protein
Sponsor: University of Alberta
Not yet recruiting
Efficacy of Adaptogens in Patients With Long COVID-19 - Condition: Covid19
Interventions: Dietary Supplement: ADAPT-232 oral solution; Other: Placebo oral solution
Sponsors: Swedish Herbal Institute AB; National Family Medicine Training Centre, Georgia; Tbilisi State Medical University; Phytomed AB
Not yet recruiting
Effectiveness of the Adsorbed Vaccine COVID-19 (Coronavac) Among Education and Law Enforcement Professionals With Risk Factors for Severity - Condition: Covid19
Intervention: Biological: Adsorbed SARS-CoV-2 (inactivated) vaccine
Sponsors: Fundação de Medicina Tropical Dr. Heitor Vieira Dourado; Butantan Institute
Not yet recruiting
Improved Oxygen Therapy in Covid-19 - Condition: Covid19
Intervention: Other: oxygen mask
Sponsor: Region Skane
Recruiting
COVID-19 Self-Testing Through Rapid Network Distribution - Condition: Covid19
Interventions: Behavioral: COVID-19 self-test; Behavioral: COVID-19 test referral
Sponsors: University of Pennsylvania; Public Health Management Corporation
Not yet recruiting
Vitamin D3 Levels in COVID-19 Outpatients From Western Mexico - Condition: Covid19
Intervention: Dietary Supplement: Vitamin D3
Sponsor: University of Guadalajara
Completed
The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue - To circumvent time-consuming clinical trials, testing whether existing drugs are effective inhibitors of SARS-CoV-2, has led to the discovery of Remdesivir. We decided to follow this path and screened approved medications “off-label” against SARS-CoV-2. Fluoxetine inhibited SARS-CoV-2 at a concentration of 0.8 µg/ml significantly in these screenings, and the EC50 was determined with 387 ng/ml. Furthermore, Fluoxetine reduced viral infectivity in precision-cut human lung slices showing its…
Unique and complementary suppression of cGAS-STING and RNA sensing- triggered innate immune responses by SARS-CoV-2 proteins - The emergence of SARS-CoV-2 has resulted in the COVID-19 pandemic, leading to millions of infections and hundreds of thousands of human deaths. The efficient replication and population spread of SARS-CoV-2 indicates an effective evasion of human innate immune responses, although the viral proteins responsible for this immune evasion are not clear. In this study, we identified SARS-CoV-2 structural proteins, accessory proteins, and the main viral protease as potent inhibitors of host innate…
Resveratrol-mediated Attenuation of Superantigen-driven Acute Respiratory Distress Syndrome is Mediated by Microbiota in the Lungs and Gut - Acute Respiratory Distress Syndrome (ARDS) is triggered by a variety of agents, including Staphylococcal Enterotoxin B (SEB). Interestingly, a significant proportion of patients with COVID-19, also develop ARDS. In the absence of effective treatments, ARDS results in almost 40% mortality. Previous studies from our laboratory demonstrated that resveratrol (RES), a stilbenoid, with potent anti-inflammatory properties can attenuate SEB-induced ARDS. In the current study, we investigated the role of…
Inhibition of interferon-stimulated gene 15 and lysine 48-linked ubiquitin binding to the SARS-CoV-2 papain-like protease by small molecules: In silico studies - The SARS-CoV-2 papain-like protease (PL^(pro)) is a suitable target for drug development, and its deubiquitinating and deISGylating activities have also been reported. In this study, molecular docking was used to investigate the binding properties of a selection of dietary compounds and naphthalene-based inhibitors to the previously characterised binding site of GRL-0617. The structures of the SARS-CoV-2 and SARS-CoV PL^(pro) in complex with interferon-stimulated gene 15 (ISG15) and lysine 48…
Antiviral activity of oleandrin and a defined extract of Nerium oleander against SARS-CoV-2 - With continued expansion of the coronavirus disease (COVID-19) pandemic, caused by severe acute respiratory syndrome 2 (SARS-CoV-2), both antiviral drugs as well as effective vaccines are desperately needed to treat patients at high risk of life-threatening disease. Here, we present in vitro evidence for significant inhibition of SARS-CoV-2 by oleandrin and a defined extract of N. oleander (designated as PBI-06150). Using Vero cells, we found that prophylactic (pre-infection) oleandrin (as…
Umifenovir and coronavirus infections: a review of research results and clinical practice - Coronaviruses are known to cause acute respiratory infections. Antiviral therapy, including for COVID-19, is based on clinical practice, experimental data and trial results. The purpose of this review is to: provide and systematize actual preclinical data, clinical trials results and clinical practice for antiviral agent umifenovir (Arbidol). Databases Scopus, Web of Science, RSCI and medRxiv were used for publication searching from 2004. A meta-analysis of clinical trials results was performed….
Tocilizumab: From Rheumatic Diseases to Covid-19 - Tocilizumab is a humanised interleukin-6 receptor-inhibiting monoclonal antibody that is currently approved for the treatment of rheumatoid arthritis and other immune-related conditions. Recently, tocilizumab has been investigated as a possible treatment for severe coronavirus-induced disease 2019 (COVID-19). Despite the lack of direct antiviral effects, tocilizumab could reduce the immune-induced organ damage caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV2) infection. Until…
Cinnamon and Hop Extracts as Potential Immunomodulators for Severe COVID-19 Cases - No abstract
Identification of the absorbed ingredients and metabolites in rats after an intravenous administration of Tanreqing injection using high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry - The metabolic profiles of Tanreqing injection, which is a traditional Chinese medicine recommended for complementary administration to treat a novel coronavirus, have remained unclear, which inhibits the understanding of the effective chemical compounds of Tanreqing injection. In this study, a sensitive high-performance liquid chromatography quadrupole time-of-flight mass spectrometry method was used to identify the compounds and metabolites in various biosamples, including plasma, bile, liver,…
SARS-CoV-2, SARS-CoV-1, and HIV-1 derived ssRNA sequences activate the NLRP3 inflammasome in human macrophages through a non-classical pathway - Macrophages promote an early host response to infection by releasing pro-inflammatory cytokines such as interleukin-1β (IL-1β), TNF, and IL-6. The bioactivity of interleukin-1β is classically dependent upon NLRP3 inflammasome activation which culminates in caspase-1 activation and pyroptosis. Recent studies suggest a role for NLRP3 inflammasome activation in lung inflammation and fibrosis in both COVID-19 and SARS, and there is evidence of NLRP3 involvement in HIV-1 disease. Here, we show that…
Discovering Potential RNA Dependent RNA Polymerase Inhibitors as Prospective Drugs Against COVID-19: An in silico Approach - COVID-19, caused by Severe Acute Respiratory Syndrome Corona Virus 2, is declared a Global Pandemic by WHO in early 2020. In the present situation, though more than 180 vaccine candidates with some already approved for emergency use, are currently in development against SARS-CoV-2, their safety and efficacy data is still in a very preliminary stage to recognize them as a new treatment, which demands an utmost emergency for the development of an alternative anti-COVID-19 drug sine qua non for a…
The Potential Therapeutic Effect of RNA Interference and Natural Products on COVID-19: A Review of the Coronaviruses Infection - The SARS-CoV-2 virus was reported for the first time in Wuhan, Hubei Province, China, and causes respiratory infection. This pandemic pneumonia killed about 1,437,835 people out of 61,308,161cases up to November 27, 2020. The disease’s main clinical complications include fever, recurrent coughing, shortness of breath, acute respiratory syndrome, and failure of vital organs that could lead to death. It has been shown that natural compounds with antioxidant, anticancer, and antiviral activities…
Artemisia annua L. extracts inhibit the in vitro replication of SARS-CoV-2 and two of its variants - CONCLUSIONS: A. annua extracts inhibit SARS-CoV-2 infection, and the active component(s) in the extracts is likely something besides artemisinin or a combination of components that block virus infection at a step downstream of virus entry. Further studies will determine in vivo efficacy to assess whether A. annua might provide a cost-effective therapeutic to treat SARS-CoV-2 infections.
The SARS-CoV-2 Y453F mink variant displays a pronounced increase in ACE-2 affinity but does not challenge antibody neutralization - SARS-CoV-2 transmission from humans to animals has been reported for many domesticated species, including farmed minks. The identification of novel spike gene mutations appearing in minks has raised major concerns about potential immune evasion and challenges for the global vaccine strategy. One genetic variant, known as “cluster-five”, arose among farmed minks in Denmark and resulted in a complete shutdown of the world’s largest mink production. However, the functional properties of this new…
Research Progress of Mesenchymal Stem Cell Therapy for Severe COVID-19 - Corona Virus Disease 2019 (COVID-19) refers to a type of pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. 60 million confirmed cases have been reported worldwide until November 29, 2020. Unfortunately, the novel coronavirus is so extremely contagious that the mortality rate of severe and critically ill patients was high. Thus, there is no definite and effective treatment in clinic except for antiviral therapy and supportive therapy. Mesenchymal stem…
Peptides and their use in diagnosis of SARS-CoV-2 infection - - link
A PROCESS FOR SUCCESSFUL MANAGEMENT OF COVID 19 POSITIVE PATIENTS - - link
Sars-CoV-2 vaccine antigens - - link
SARS-COV-2 BINDING PROTEINS - - link
Lüftungssystem für einen mit öffnbaren Fenstern (16) ausgestatteten Gebäuderaum, gekennzeichnet dadurch, dass es ein Gehäuse (18) und einen Ventilator (20) aufweist, wobei durch das Gehäuse eine vom Ventilator erzeugte Luftströmung strömen kann, wobei das Gehäuse dafür eine Einströmöffnung (24) für Luft und eine Ausströmöffnung (22) für Luft enthält, wobei eine der beiden Öffnungen der Form eines Öffnungsspalts (26) zwischen einem Fensterflügel (12) und einem Blendrahmen (14) des Fensters (16) angepasst ist.
Compositions and methods for detecting SARS-CoV-2 spike protein - - link
靶向SARS-CoV-2的抗体及其制备方法和应用 - 本发明提供了靶向SARS‑CoV‑2的抗体及其制备方法和应用,该抗体包含VH和VL,所述VH包含以下CDR:氨基酸序列如SEQ ID NO:1、2、3所示的VH CDR1、VH CDR2、VH CDR3;所述VL包含以下的CDR:氨基酸序列如SEQ ID NO:4、5、6所示的VL CDR1、VL CDR2、VL CDR3。该抗体能够高亲和且特异地结合SARS‑CoV‑2的S蛋白的RBD,抑制RBD蛋白与受体ACE2蛋白的结合,高效地抑制SARS‑CoV‑2感染细胞,同时对潜在的免疫逃逸突变的假病毒具有很好的中和活性,从而可有效应用于SARS‑CoV‑2病毒及相关疾病的诊断、预防和治疗中。 - link
Desinfektionsvorrichtung (100, 200A, 200B, 300) zum Desinfizieren einer berührungsintensiven Oberfläche, umfassend: eine EWE-Vorrichtung (110) zum Emittieren von elektromagnetischen Wellen, die dafür konfiguriert ist, elektromagnetische Strahlung innerhalb des ultravioletten Spektrums (UV-Strahlung, 115) zu emittieren; und einer als Lichtleiter dienenden, mindestens teilweise für sichtbares Licht zwischen der vorderen Oberfläche (121) und der hinteren Oberfläche (122, 222) durchlässigen Scheibe (120, 220A, 220B) mit einer vorderen Oberfläche (121) und einer hinteren Oberfläche (122, 222), wobei die EWE-Vorrichtung (110) positioniert ist, um UV-Strahlung (115) in die Scheibe (120, 220A, 220B) zu emittieren, wobei die Scheibe dafür konfiguriert ist, einen Teil der von der EWE-Vorrichtung (110) empfangenen UV-Strahlung (115) in einer verteilten Art und Weise über die vordere Oberfläche (121) zu reflektieren und zu zerstreuen; und die UV-Strahlung, die von der Scheibe (120, 220A, 220B) empfangen und über die vordere Oberfläche (121) verteilt wird, zur Desinfektion der vorderen Oberfläche dient.
一种SARS-CoV-2中和抗体的检测方法、检测试剂盒 - 本发明公开了一种SARS‑CoV‑2中和抗体的检测方法、检测试剂盒,属于生物医学检测技术领域。本发明公开的SARS‑CoV‑2中和抗体的检测方法是基于hACE2‑RBD放大的胶乳增强免疫比浊检测法,检测试剂盒包括SARS‑CoV‑2的S蛋白受体结合域RBD标记的第一胶乳微球和人hACE2标记的第二胶乳微球。本发明通过在胶乳微球上标记抗原,放大了检测信号,增加了检测的灵敏度,拓宽了检测范围。本发明不仅能够确定被检测者是否为感染者,还能获知被检测者感染风险。本发明对中和抗体的检测还可用于评价接种SARS‑CoV‑2疫苗后临床效果,对SARS‑CoV‑2疫苗的研发与接种,具有重大意义。 - link
Anordnung zum Versprühen einer Substanz in die menschliche Mundhöhle und/oder in den Rachen, dadurch gekennzeichnet, dass die Anordnung eine Sprühflasche mit einer Substanz aufweist, die wenigstens Aroniasaft und eine Alkoholkomponente aufweist.